MENU

Kamau Therapeutics: Nula-cel RMAT designation and SCD trial data

Markets Insider(GlobeNewswire) USA
Overview
Kamau Therapeutics has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for nula-cel, a gene-corrected stem cell therapy for sickle cell disease. Preliminary Phase 1/2 RESTORE trial data shows all three patients treated with the optimized process achieved transfusion independence and zero vaso-occlusive events. This therapy aims to provide a lifelong cure by correcting the root mutation rather than compensating with fetal hemoglobin.
In Depth

Key Findings

The U.S. Food and Drug Administration (FDA) has granted RMAT designation to nula-cel, an investigational stem cell medicine for sickle cell disease (SCD). This designation is based on preliminary clinical evidence from the Phase 1/2 RESTORE trial. In this trial, all three patients treated via the optimized manufacturing process achieved transfusion independence and experienced no vaso-occlusive events. Furthermore, two patients with over six months of follow-up demonstrated sickle hemoglobin levels below 20%, which is under the 30% threshold targeted for stroke prevention, showing a predominantly adult hemoglobin profile.

Technical Details

Nula-cel utilizes ex vivo homology-directed repair (HDR) to precisely engineer a patient’s own long-lived blood stem cells outside the body. Unlike other therapies that induce fetal hemoglobin to compensate for the disease, nula-cel is designed to correct the sickle mutation itself, converting it into the normal adult β-globin sequence. This ex vivo approach allows Kamau Therapeutics to verify the quality, identity, potency, and safety of each cell product before it is returned to the patient. Because these engineered cells self-renew, the treatment is designed as a one-time intervention to provide durable, potentially lifelong benefits.

Background & Context

Sickle cell disease is an inherited disorder affecting approximately 100,000 people in the U.S. and millions globally. A mutation in the β-globin gene produces sickle hemoglobin (HgbS), leading to chronic hemolysis, pain crises, and organ damage. While existing therapies reduce pain crises, they do not restore native adult hemoglobin (HgbA) or consistently maintain HgbS levels below 30%, a level associated with stroke prevention in ASH guidelines.

Significance & Outlook

The RMAT designation allows Kamau Therapeutics to engage in more frequent interactions with the FDA to align on the path toward a registrational dataset. The company plans to request a multidisciplinary RMAT meeting to discuss endpoints for accelerated approval and the potential for priority review. Nula-cel has also previously received Fast Track and Orphan Drug designations from the FDA.

Source: https://markets.businessinsider.com/news/stocks/kamau-therapeutics-receives-fda-regenerative-medicine-advanced-therapy-rmat-designation-for-nula-cel-a-gene-corrected-stem-cell-therapy-for-sickle-cell-disease-1036755594

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.

  • Your email and selected fields are used only to deliver the newsletter.
  • We never share your information with third parties.
  • You can unsubscribe anytime via the link in each email.

See our Privacy Policy for details.

Takes about a minute · Unsubscribe anytime

Published by Troy-Technical, an independent site run by one engineer with a career in materials development.
About the author / Contact info@troy-technical.jp
Let's share this post !

Author of this article

TOC